Background: Therapeutic plasma exchange (TPE) has been recommended by guidelines for the treatment of anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) with severe kidney dysfunction. In recent years, some researchers have proposed that double-filtration plasmapheresis (DFPP) can also be used effectively in the treatment of these patients, but the difference between the 2 modalities of plasmapheresis is not clear. Methods: In this retrospective cohort study of AAV patients with serum creatinine ≥500 μmol/L from March 2013 to July 2018 who received TPE or DFPP treatment, we compared TPE and DFPP in terms of the changes of clinical parameters before and after plasmapheresis, the rates of adverse events during plasmapheresis, and kidney and patient survival during follow-up. Results: Forty-two AAV patients with kidney injury were included in this study. Twenty patients were treated with TPE and 22 patients were treated with DFPP. All patients were followed up for a median of 22 months. In each group, there were 10 deaths, and 6 patients developed end-stage kidney disease (ESKD). There were no significant differences between TPE and DFPP in terms of the changes of renal function or other laboratory results after treatment. During the plasmapheresis treatment, there was no significant difference in the rate of adverse events (p = 0.67). During the follow-up, there was no difference between the groups regarding the level of serum creatinine for patients with kidney recovery. The hazard ratio (HR) for TPE compared to DFPP for the outcome of ESKD was 0.92 (95% CI 0.45–1.9; p = 0.79) and the HR for death was 1.11 (95% CI 0.45–2.76; p = 0.82). Conclusion: There were no differences in short-term effectiveness, safety, or long-term outcomes between the 2 modalities of plasmapheresis. Our study suggests that DFPP may be a choice of plasmapheresis for AAV patients with severe kidney injury especially in countries and regions with limited blood resources.

Keywords:
Therapeutic plasma exchange, Double-filtration plasmapheresis, Anti-neutrophil cytoplasmic antibodies-associated vasculitis, Kidney injury
1.
Segelmark M, Wieslander J. IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA).
Nephrol Dial Transplant
. 1993;8(8):696–702.
2.
Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.
Proc Natl Acad Sci USA
. 1990 Jun;87(11):4115–9.
3.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides.
Arthritis Rheum
. 2013 Jan;65(1):1–11.
4.
Watanabe K, Tani Y, Kimura H, Tanaka K, Hayashi Y, Asahi K, et al. Clinical outcomes of Japanese MPO-ANCA-related nephritis: significance of initial renal death for survival.
Intern Med
. 2012;51(15):1969–76.
5.
Chen M, Yu F, Zhang Y, Zhao MH. Clinical [corrected] and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre.
Postgrad Med J
. 2005 Nov;81(961):723–7.
6.
Aasarød K, Iversen BM, Hammerstrøm J, Bostad L, Vatten L, Jørstad S. Wegener’s granulomatosis: clinical course in 108 patients with renal involvement.
Nephrol Dial Transplant
. 2000 May;15(5):611–8.
7.
Hu WX, Liu ZH, Liu CB, Tang Z, Wang QW, Chen HP, et al. Prognosis of microscopic polyangiitis with renal involvement: report of 60 Chinese patients.
Chin Med J (Engl)
. 2005 Dec;118(24):2089–92.
8.
Chen X, Chen N. Plasma exchange in the treatment of rapidly progressive glomerulonephritis.
Contrib Nephrol
. 2013;181:240–7.
9.
Nishida R, Kaneko S, Usui J, Kawamura T, Tsunoda R, Tawara T, et al. Plasma Exchange Is Highly Effective for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patients With Rapidly Progressive Glomerulonephritis Who Have Advanced to Dialysis Dependence: A Single-Center Case Series.
Ther Apher Dial
. 2019 Jun;23(3):253–60.
10.
Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis.
Am J Kidney Dis
. 2011 Apr;57(4):566–74.
11.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.
J Clin Apher
. 2019 Jun;34(3):171–354.
12.
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.
Ann Rheum Dis
. 2016 Sep;75(9):1583–94.
13.
Chen Y, Yang L, Li K, Liu Z, Gong D, Zhang H, et al. Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis With Severe Renal Failure: A Preliminary Study of 15 Patients.
Ther Apher Dial
. 2016 Apr;20(2):183–8.
14.
Gong D, Ji D, Xu B, Liu Z. More selective removal of myeloperoxidase-anti-neutrophil cytoplasmic antibody from the circulation of patients with vasculitides using a novel double-filtration plasmapheresis therapy.
Ther Apher Dial
. 2013 Feb;17(1):93–8.
15.
Iwatani H, Uzu T, Kakihara M, Nakayama Y, Kanasaki K, Yamato M, et al. A case of Wegener’s granulomatosis with pulmonary bleeding successfully treated with double filtration plasmapheresis (DFPP).
Clin Exp Nephrol
. 2004 Dec;8(4):369–74.
16.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al.; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.
J Am Soc Nephrol
. 2007 Jul;18(7):2180–8.
17.
Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear.
Kidney Int
. 2013 Aug;84(2):397–402.
18.
Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease.
Nat Rev Rheumatol
. 2014 Aug;10(8):463–73.
19.
Gashti CN, Andreoli DC, Patel D. Membrane-based therapeutic plasma exchange (mTPE): technical and clinical experience.
J Clin Apher
. 2018 Feb;33(1):38–45.
20.
Tanna A, Guarino L, Tam FW, Rodriquez-Cubillo B, Levy JB, Cairns TD, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors.
Nephrol Dial Transplant
. 2015 Jul;30(7):1185–92.
21.
Lyu RK, Chen WH, Hsieh ST. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barré syndrome.
Ther Apher
. 2002 Apr;6(2):163–6.
22.
Su YJ, Chiu WC, Hsu CY, Chen JB, Ng HY. Lower In-Hospital Mortality with Plasma Exchange than Plasmapheresis in a Subgroup Analysis of 374 Lupus Patients.
BioMed Res Int
. 2018 May;2018:9707932.
23.
Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management.
Am J Kidney Dis
. 1994 Jun;23(6):817–27.
24.
Yeh JH, Chen WH, Chiu HC. Complications of double-filtration plasmapheresis.
Transfusion
. 2004 Nov;44(11):1621–5.
25.
Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, Marshall JC, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis.
Crit Care
. 2014 Dec;18(6):699.
26.
Irani MS, Toushan M, Zhang L, Simpson PM, Karafin MS. Risk of hypotensive reactions is increased when using partial saline replacement for therapeutic plasma exchange.
J Clin Apher
. 2019 Oct;34(5):524–7.
27.
Flythe JE, Brunelli SM. Blood pressure variability among chronic dialysis patients: recent advances in knowledge.
Curr Opin Nephrol Hypertens
. 2015 Mar;24(2):163–9.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.